Literature DB >> 18367013

Management of arterial hypertension in obese patients.

Ulrich O Wenzel1, Christian Krebs.   

Abstract

Obesity prevalence is increasing. Obesity frequently coexists with-and can cause or worsen-arterial hypertension. However, no current guidelines provide specific recommendations. Antihypertensive drug treatment is indicated in most obese hypertensive patients, leading to the obvious question: what is the best drug treatment for this population? Some antihypertensive agents may have unwanted effects on the metabolic and hemodynamic abnormalities linking obesity and hypertension. Without adequate studies, recommendations for or against each class of antihypertensive agents are based on subjective criteria and pathophysiologic assumptions. Diuretics and beta-blockers have unwanted effects, whereas calcium antagonists are metabolically neutral, and angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers may increase insulin sensitivity. The renin-angiotensin system in adipose tissue has been implicated in arterial hypertension, and sodium retention is central to obesity-related hypertension. Therefore, an ACE inhibitor or diuretic should be considered as first-line antihypertensive drug therapy in obesity-hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18367013     DOI: 10.1007/s11906-007-0090-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  52 in total

1.  History about the discovery of the renin-angiotensin system.

Authors:  N Basso; N A Terragno
Journal:  Hypertension       Date:  2001-12-01       Impact factor: 10.190

2.  Who cares about the obese hypertensive patient?

Authors:  A M Sharma; S Rössner
Journal:  J Intern Med       Date:  2002-05       Impact factor: 8.989

3.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 4.  Cardiovascular regulation in obesity-induced hypertension.

Authors:  A P Rocchini
Journal:  Hypertension       Date:  1992-01       Impact factor: 10.190

5.  Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites.

Authors:  Michael Schupp; Lucas D Lee; Nikolaj Frost; Sumaira Umbreen; Boris Schmidt; Thomas Unger; Ulrich Kintscher
Journal:  Hypertension       Date:  2005-12-19       Impact factor: 10.190

6.  Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.

Authors:  Ralf A Benndorf; Tanja Rudolph; Daniel Appel; Edzard Schwedhelm; Renke Maas; Friedrich Schulze; Elisabeth Silberhorn; Rainer H Böger
Journal:  Metabolism       Date:  2006-09       Impact factor: 8.694

Review 7.  Oral renin inhibitors.

Authors:  Jan A Staessen; Yan Li; Tom Richart
Journal:  Lancet       Date:  2006-10-21       Impact factor: 79.321

Review 8.  Pathophysiology and treatment of obesity hypertension.

Authors:  Marion R Wofford; John E Hall
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

9.  Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats.

Authors:  C Krebs; I Hamming; S Sadaghiani; O M Steinmetz; C Meyer-Schwesinger; S Fehr; R A K Stahl; I M Garrelds; A H J Danser; H van Goor; A Contrepas; G Nguyen; U Wenzel
Journal:  Kidney Int       Date:  2007-06-27       Impact factor: 10.612

10.  Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms.

Authors:  Y Huang; S Wongamorntham; J Kasting; D McQuillan; R T Owens; L Yu; N A Noble; W Border
Journal:  Kidney Int       Date:  2006-01       Impact factor: 18.998

View more
  2 in total

1.  Obesity-related hypertension.

Authors:  Richard N Re
Journal:  Ochsner J       Date:  2009

Review 2.  The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome.

Authors:  Kelly Putnam; Robin Shoemaker; Frederique Yiannikouris; Lisa A Cassis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-06       Impact factor: 4.733

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.